Robotics- and AI-based hospital and home rehabilitation for children with spinal cord injury
| ISRCTN | ISRCTN19102055 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN19102055 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | 2263 |
| Sponsor | Inrobics Social Robotics, S.L. |
| Funders | Inrobics Social Robotics, S.L., Agencia Estatal de Investigación, Ministerio de Ciencia, Innovación y Universidades |
- Submission date
- 29/10/2025
- Registration date
- 29/10/2025
- Last edited
- 29/10/2025
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Injury, Occupational Diseases, Poisoning
Plain English summary of protocol
Background and study aims
This study explores how assistive social robotics and artificial intelligence can enhance rehabilitation for children with spinal cord injury. The goal is to assess the usability, satisfaction, and effectiveness of the INROBICS platform - a robotic system designed to support physical therapy both in hospital and at home.
Who can participate?
Children aged 7–16 years with spinal cord injury below the C6 level, who are clinically stable and can sit independently, will be invited to participate. Participants must have parental consent.
What does the study involve?
Participants will be randomly assigned to one of two groups. The intervention group will complete 15 rehabilitation sessions using the INROBICS robot at the hospital and 15 sessions at home using the virtual version. The control group will receive 30 conventional therapy sessions. Each session includes warm-up, main exercise, and cool-down phases. Assessments will be performed before, during, and after treatment, and again three months later.
What are the possible benefits and risks of participating?
The Inrobics Rehab system may improve rehabilitation engagement, motor recovery, and emotional wellbeing. Risks are minimal and similar to standard therapy; sessions are supervised by rehabilitation professionals.
Where is the study run from?
The study is conducted at the Hospital Nacional de Parapléjicos (Toledo, Spain) in collaboration with Inrobics Social Robotics, S.L.
When is the study starting and how long is it expected to run for?
March 2024 to February 2027
Who is funding the study?
The study is funded by the Ministry of Science, Innovation and Universities (Spain), under the Public–Private Collaboration Programme 2023
Who is the main contact?
Dr Ana de los Reyes Guzmán, adlos@sescam.jccm.es
Contact information
Scientific, Principal investigator
FINCA DE, Carr. de la Peraleda S/N
Toledo
45004
Spain
| Phone | +34 (0)925247700 |
|---|---|
| adlos@sescam.jccm.es |
Public
Av. Gregorio Peces Barba 1
Madrid
28919
Spain
| 0009-0003-5104-0491 | |
| Phone | +34 (0)630423231 |
| fgarcia@inrobics.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Clinical, analytical, experimental, prospective, randomized controlled study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Hospital and home rehabilitation based on social assistive robotics and artificial intelligence for paediatric patients |
| Study objectives | The general objective of the study is to analyse the user experience, usability and effectiveness of the Inrobics Rehab platform based on Social Assistance Robotics and Artificial Intelligence. |
| Ethics approval(s) |
Approved 24/09/2025, Ethics Committee for Clinical Research with Medicines at the Toledo University Hospital Complex (Av. del Río Guadiana, Toledo, 45007, Spain; +34 (0)925269200 extension: 48557; ceic-chto-secretario@sescam.jccm.es), ref: 2263 |
| Health condition(s) or problem(s) studied | Paediatric school patients aged between 7 and 16 years with subacute or chronic spinal cord injury |
| Intervention | Participants will be randomly assigned to either the intervention group or the control group using a simple randomisation technique. A computer-generated list of random numbers will determine treatment allocation, which will be concealed in sequentially numbered, sealed envelopes. Each participant receives the envelope in order of enrolment, revealing assignment to either the INROBICS intervention group or the control group. 1. Intervention group: each participant will complete 15 sessions with the INROBICS Clinic platform and 15 with INROBICS Virtual spread over 4 weeks. 2. Control group: each participant will receive 30 experimental sessions of conventional therapy over 4 weeks. |
| Intervention type | Device |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Inrobics Rehab |
| Primary outcome measure(s) |
Assessments are conducted at four timepoints: T0 (baseline evaluation), T1 (post-clinical intervention), T2 (post-virtual intervention), and T3 (3-month follow-up) |
| Key secondary outcome measure(s) |
Assessments are conducted at four timepoints: T0 (baseline evaluation), T1 (post-clinical intervention), T2 (post-virtual intervention), and T3 (3-month follow-up) |
| Completion date | 28/02/2027 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Lower age limit | 7 Years |
| Upper age limit | 16 Years |
| Sex | All |
| Target sample size at registration | 52 |
| Key inclusion criteria | 1. Aged between 7 and 16 years old 2. Clinically stable 3. Diagnosis of spinal cord injury below C6 in cases of AIS (ASIA Impairment Scale) severity A or B, or any level of incomplete spinal cord injury that allows reach with the upper limbs 4. Independent sitting (including technical aids such as belts, wedges, trunk supports, etc) 5. Parents, guardians or family members must have signed the corresponding informed consent form |
| Key exclusion criteria | 1. Unstable orthopaedic injuries such as unconsolidated fractures or unstable osteosynthesis systems in the upper limbs 2. Suffering from severe pain, joint stiffness and/or severe spasticity in the upper limbs 3. Severe bronchopneumopathy and/or heart disease requiring monitoring during exercise or a history of abnormal response to physical exertion prior to spinal cord injury 4. Severe visual impairments, cognitive impairment and/or incapacitating psychiatric illness |
| Date of first enrolment | 01/11/2025 |
| Date of final enrolment | 02/02/2027 |
Locations
Countries of recruitment
- Spain
Study participating centre
Toledo
45004
Spain
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | Data sharing plans for the current study are unknown and will be available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Protocol file | 29/10/2025 | No | No | ||
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Additional files
- 48307_PROTOCOL.pdf
- Protocol file
Editorial Notes
29/10/2025: Study's existence confirmed by the Ethics Committee for Clinical Research with Medicines at the Toledo University Hospital Complex.